Sunday, December 1, 2019

Suven#39;s Alzheimer#39;s molecule fails to meet primary end point in phase-2 trial

Suven#39;s Alzheimer#39;s molecule fails to meet primary end point in phase-2 trial SUVN-502#39;s clinical trial data assumed significance as no new Alzheimer#39;s drug has been approved since Forest Labs#39; Namenda in 2003

from Moneycontrol Business News https://ift.tt/2DDy6ny

No comments:

Post a Comment

D-St surges 1% on reports govt to cut tax on foreign bond bets

Indian stock markets surged on Thursday. The Nifty and Sensex saw significant gains. This rise was driven by reports of a potential tax cut ...